Biological

Dendritic Cell-MART-1 Peptide Vaccine clinical trials

studies test it: 3
open now: 0
in phase 3: 0
first study started: 1997

How studies write it

Studies that test it under each name

Name

dendritic cell-MART-1 peptide vaccine: 3

Studies by the year they started

3 studies that test it; most in 1997 (1)

Studies that test Dendritic Cell-MART-1 Peptide Vaccine, by start year
Year	Studies
1997	1
1999	1
2002	1

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it.

Melanoma: 3

Who runs them

Industry 0 · Other 3

Jonsson Comprehensive Cancer Center (2) · National Cancer Institute (NCI) (1)

Often tested with

Tested in the same studies.

GP-100 antigen (1) · Therapeutic Tumor Infiltrating Lymphocytes (1) · Tyrosinase Peptide (1)

Studies

Open first, then newest update. How each study uses Dendritic Cell-MART-1 Peptide Vaccine is read from its arms, and is right about nine times in ten.

Testing it · 3

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant MelanomaCompletedPhase 1/2Jonsson Comprehensive Cancer CenterNCT00039325Written as dendritic cell-MART-1 peptide vaccine
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant MelanomaCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT00005617Written as dendritic cell-MART-1 peptide vaccine
Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedPhase 1National Cancer Institute (NCI)NCT00003665Written as dendritic cell-MART-1 peptide vaccine